Single injection of ebronucimab in healthy Chinese men
This trial tests a single injection of a new drug called ebronucimab to see how safe it is in healthy Chinese men. It may help lower cholesterol, but this is an early-phase study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy Chinese man aged 18 to 60.
- Your weight should be between 60 and 80 kilograms, and your body mass index (BMI) should be between 19 and 26.
- Your cholesterol (LDL-C) must be between 1.8 and 4.9 mmol/L.
- You must not have used PCSK9 inhibitor drugs (like evolocumab) in the past year.
- You must not have allergies to the drug or to monoclonal antibodies.
- You must not have a history of organ transplantation, drug abuse, or abnormal vital signs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called ISH0613 in healthy volunteers to see if it is safe and how the body processes it. It is the first time this drug is given to humans.
This study tests a new medicine called BEBT-701 for people with mild to moderate high blood pressure and high cholesterol. The goal is to see if it can lower both blood pressure and LDL ('bad') cholesterol safely.
This trial is testing an investigational drug to see how it moves through the body and how it affects the immune system. It is only for healthy Chinese adults, and results will help guide future studies.
This trial tests a new medicine called HB0034 in healthy volunteers. It helps researchers understand how the drug works in the body before testing it in people with a medical condition.
This study tests a new antibody-based drug in healthy volunteers to see how safe it is and how the body handles it. Participants will receive a single injection and be monitored closely for a few months.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
Hear when a new Healthy Subjects (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.